fda bpc-157 immunogenicity concerns Photos by Prof. Patrick J. Treacy (@ptreacy) · April 17, 2026 FDA's Overreach on Compounded Peptides

Contraindications Semaglutide methylcobalamin ODT should not be used by individuals with: Personal or family history of medullary thyroid carcinoma (MTC) Multiple endocrine neoplasia syndrome type 2 (MEN 2) Known hypersensitivity to semaglutide or any formulation component History of severe pancreatitis Severe gastrointestinal disease that may be worsened by delayed gastric emptying Severe renal impairment Pregnancy or planned pregnancy The methylcobalamin component has no meaningful contraindications at the doses used

Most of what is known comes from: So when someone searches for BPC 157 weight loss, it is important to set expectations right away: this is not comparable to clinically validated obesity therapies backed by decades of clinical outcome data, standardized dosing, and predictable effects on appetite and metabolic pathways, such as FDA-approved options like semaglutide (Wegovy) and tirzepatide (Zepbound)

Patients who are experiencing low levels of human growth hormone (HGH) may be prescribed Sermorelin Acetate, though it can also be recommended for patients focusing on weight loss and athletic performance

Goyal RK, Chaudhury A (2010) Mounting evidence against the role of ICC in neurotransmission to smooth muscle in the gut